<li>almotriptan<p>fluoxetine, almotriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>azithromycin<p>azithromycin and fluoxetine both increase  QTc interval. Minor/Significance Unknown.</p></li><li>bumetanide<p>bumetanide, fluoxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>celandine<p>celandine decreases effects of fluoxetine by pharmacodynamic antagonism. Minor/Significance Unknown. Based on animal studies.</p></li><li>chloroquine<p>chloroquine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>codeine<p>fluoxetine decreases effects of codeine by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of codeine to active metabolite morphine.</p></li><li>darifenacin<p>darifenacin will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>dexmethylphenidate<p>dexmethylphenidate increases effects of fluoxetine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>diphenhydramine<p>diphenhydramine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>duloxetine<p>duloxetine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>eletriptan<p>fluoxetine, eletriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>esomeprazole<p>fluoxetine will increase the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>ethacrynic acid<p>ethacrynic acid, fluoxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>frovatriptan<p>fluoxetine, frovatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>furosemide<p>furosemide, fluoxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>hydrocodone<p>fluoxetine decreases effects of hydrocodone by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of hydrocodone to active metabolite morphine.</p></li><li>lansoprazole<p>fluoxetine will increase the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>lithium<p>fluoxetine, lithium. Mechanism: unknown. Minor/Significance Unknown. Risk of neurotoxicity.</p></li><li>losartan<p>fluoxetine decreases effects of losartan by decreasing metabolism. Minor/Significance Unknown. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>maraviroc<p>maraviroc will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>marijuana<p>marijuana will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>methylphenidate<p>methylphenidate increases effects of fluoxetine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>mibefradil<p>mibefradil will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>naratriptan<p>fluoxetine, naratriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>omeprazole<p>fluoxetine will increase the level or effect of omeprazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>panax ginseng<p>panax ginseng increases effects of fluoxetine by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>parecoxib<p>parecoxib will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>pazopanib<p>fluoxetine and pazopanib both increase  QTc interval. Minor/Significance Unknown.</p></li><li>pleurisy root<p>pleurisy root decreases effects of fluoxetine by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.</p></li><li>quinacrine<p>quinacrine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>rabeprazole<p>fluoxetine will increase the level or effect of rabeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>ranolazine<p>ranolazine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>ritonavir<p>ritonavir will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>rizatriptan<p>fluoxetine, rizatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>ruxolitinib<p>fluoxetine will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>sumatriptan<p>fluoxetine, sumatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan intranasal<p>fluoxetine, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan transdermal<p>fluoxetine, sumatriptan transdermal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>torsemide<p>torsemide, fluoxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>venlafaxine<p>venlafaxine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>zolmitriptan<p>fluoxetine, zolmitriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li>